[{"id":"19a18864-7900-47b9-9910-14ea9b2a17e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05514158","created_at":"2022-08-24T21:07:48.157Z","updated_at":"2024-07-02T16:35:26.025Z","phase":"Phase 1","brief_title":"To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)","source_id_and_acronym":"NCT05514158","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • RC98"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/28/2022","start_date":" 09/28/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2023-12-18"}]